Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

EQS-News: ABIVAX / Key word(s): AGM/EGM Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents 20.04.2026 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026

Availability of the Preparatory Documents

PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting (the “General Meeting”) will be held on May 11, 2026, at 3:00 pm (CEST), at the hotel Paris Marriott Opera Ambassador, located at 16 boulevard Haussmann in Paris (75009), France.

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) of April 3, 2026 (N°2600756).

The information and preparatory documents for this General Meeting are made available to the Company’s shareholders in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions. The documents referred to in Article R.22-10-23 of the French Commercial Code are available on the Company’s website: www.abivax.com

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
[e-mail]
[phone]

---

20.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

---

2311506  20.04.2026 CET/CEST